文献速递前列腺癌

合并症与PSA倍增时间对不良风险前列腺癌放疗联合或不联合雄激素剥夺治疗后PSA失败男性死亡风险的影响

The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-01-24

本研究基于1995至2001年随机接受单纯放疗或放疗联合6个月雄激素剥夺治疗的206例不良风险前列腺癌男性,其中108例出现PSA失败。中位随访13.71年后,PSA倍增时间延长与无/轻微合并症组前列腺癌特异性死亡风险降低相关,且与全因死亡风险降低相关;但在中/重度合并症组仅与前列腺癌特异性死亡风险降低相关,与全因死亡风险无显著关联。

要点

  • PSA失败后,无/轻微合并症男性中PSA倍增时间延长与全因死亡风险降低相关(AHR 0.69)。
  • 中/重度合并症男性中PSA倍增时间延长与全因死亡风险无显著关联(AHR 0.95)。
  • 两组中PSA倍增时间延长均与前列腺癌特异性死亡风险降低相关。

核心结论

  • 在PSA失败时决定适当管理和/或临床试验资格时,应同时考虑合并症程度和PSA倍增时间。

研究设计与样本

  • 1995年至2001年间,206例不良风险前列腺癌男性被随机分配接受单纯放疗或放疗联合6个月雄激素剥夺治疗;其中108例出现PSA失败并组成研究队列。
  • 采用Cox回归和Fine-Gray回归分析,按经验证的合并症指标分层,评估PSA倍增时间与全因死亡风险及前列腺癌特异性死亡/其他原因死亡风险的关联。

主要发现

  • PSA失败后中位随访13.71年,108例男性中81例(75%)死亡。
  • 无/轻微合并症组中,PSA倍增时间延长与前列腺癌特异性死亡风险降低相关(AHR 0.33,95%CI 0.17-0.65,P=0.001)。
  • 中/重度合并症组中,PSA倍增时间延长与前列腺癌特异性死亡风险降低相关(AHR 0.014,95%CI 0.002-0.129,P=0.0002)。
  • 无/轻微合并症组中,PSA倍增时间延长与全因死亡风险降低相关(AHR 0.69,95%CI 0.50-0.96,P=0.03)。
  • 中/重度合并症组中,PSA倍增时间延长与全因死亡风险无显著关联(AHR 0.95,95%CI 0.51-1.78,P=0.87)。

临床怎么用

  • 作者认为,在PSA失败时决定适当管理和/或临床试验资格时,应同时考虑合并症程度和PSA倍增时间。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal management of men with PSA failure following initial prostate cancer (PC) therapy stratified by comorbidity is unknown. We investigated the impact that PSA doubling time (DT) and comorbidity had on the risk of all-cause mortality (ACM), prostate cancer-specific mortality (PCSM) and other-cause mortality (OCM) following PSA failure. METHODS: Between 1995 and 2001, 206 men with unfavorable-risk PC were randomized to receive radiation therapy alone or in combination with 6 months of androgen deprivation therapy (ADT); 108 men experienced PSA failure and formed the study cohort. Cox and Fine-Gray regression analysis was used to determine whether PSA DT was associated with the risk of ACM and PCSM/OCM, respectively, stratified by comorbidity status using a validated metric. RESULTS: After a median follow-up of 13.71 years following PSA failure, 81 of the 108 men (75%) died. Longer PSA DT was associated with a decreased risk of PCSM in men with no/minimal (adjusted hazard ratio (AHR) 0.33, 95% confidence interval (CI) 0.17-0.65, P=0.001) and moderate/severe comorbidity (AHR 0.014, 95% CI 0.002-0.129, P=0.0002). However, because of the different contributions of the risk of OCM to risk of ACM within comorbidity subgroups, increasing PSA DT was only associated with a decreased risk of ACM in men with no/minimal (AHR 0.69, 95% CI 0.50-0.96, P=0.03) but not moderate/severe comorbidity (AHR 0.95, 95% CI 0.51-1.78, P=0.87). CONCLUSIONS: Both the extent of comorbidity and the PSA DT should be taken into consideration when deciding on appropriate management and/or clinical trial eligibility at the time of PSA failure.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Patel SA, Chen MH, Loffredo M, et al. The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017. PMID: 28117382. doi:10.1038/pcan.2016.74

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。